As AstraZeneca faces an ongoing investigation into alleged illegal importation of drugs in China, the company’s China business logged a sales decline in the fourth quarter of 2024. More: AstraZeneca warns of potential tax fines amid China sales slowdown, illegal
read moreAbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting off on a very different note. More: TV drug ad spending reached new heights in January, as Novartis' Pluvicto
read more
Breast cancer therapy offers hope for patients at risk of recurrence More: Novartis secures MHRA authorisation for ribociclib Source: News
read moreThe company is in talks with individual regulatory authorities after its decision to withdraw a European approval application for Izervay prompted a $760 million impairment charge. More: Astellas takes 0M charge, reveals slowdown for eye drug Izervay after regulatory stumbles
read moreWith sales of Novo Nordisk’s obesity blockbuster Wegovy more than doubling in 2024’s fourth quarter, the Danish drugmaker feels confident that it can maintain its edge over chief rival Eli Lilly in the year to come. Still, the company caveated
read moreAfter recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion by the end of the decade. More: With recent launches and more to come, Amgen's biosimilar business is trending up Source:
read more© 1994 - 2026 B.M. Pharmaceuticals